INSIGHTS ON CLINICAL TRIAL DESIGN
-
![Business Meeting-GettyImages-1831418247]( "Scaling Oncology Trials Without Losing Momentum")
Scaling Oncology Trials Without Losing MomentumAs oncology programs expand, complexity often replaces momentum. Explore how scaling introduces hidden operational challenges and why anticipating continuity early helps teams stay aligned.
-
![GettyImages-1489414892 Technological Software Engineering Department Manager Using A Laptop]( "The Future Of Patient Participation In Clinical Research")
The Future Of Patient Participation In Clinical ResearchTo address challenges such as limited patient awareness, mistrust, and logistical barriers, the industry must embrace technology-driven solutions and community-centered outreach.
-
![medidata screenshot]( "The True Science Behind eCOA, Shaped By Patient And Site Insights")
The True Science Behind eCOA, Shaped By Patient And Site InsightsThis webinar brings together patients, sites, and eCOA science to dismantle the researcher-subject hierarchy and replace it with a collaborative model.
-
![GettyImages-1759287088 patient nurse consultation]( "Reducing The Burden Of Patient Retention And Improving Continuity")
Reducing The Burden Of Patient Retention And Improving ContinuityImmunology trials often place a sustained burden on participants. However, integrating Home Trial Support (HTS) into a Phase 3 immunology trial can help improve the overall study experience.
-
Human Abuse Potential: Participant Safety5/5/2026
Explore how clinical staffing, monitoring equipment, and structured safety oversight support the safe conduct of Human Abuse Potential studies, including approaches to adverse event management.
-
Reusable RTSM Reduces Risk And Speeds Change3/9/2026
Minimize human error and accelerate timelines with a reusable software framework. Automation provides deeper testing coverage and faster mid-study updates for more resilient clinical operations.
-
FDA Draft Guidance On Diversity Action Plan Requirements10/24/2024
Explore new drafted guidance under FDORA that substantiates the mandate of a Diversity Action Plan (DAP) for late-stage trial protocol submissions.
-
Precision Medicine In Pediatrics: Biomarkers and Assay Development5/2/2025
Discover the rise in FDA-approved pediatric therapies and the role of precision medicine in tailoring treatments to genetic profiles, as well as how biomarkers and assays can enhance pediatric care.
-
Developing And Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays9/25/2025
Receptor occupancy (RO) assays assess drug-target engagement and support PK/PD modeling. Accurate RO requires customized assays using stabilized blood to monitor CD6 modulation in autoimmune therapy.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![GettyImages-2148023123-oncology-patient-appointment]( "Ready To Reach Proof Of Concept Faster?")
Proof-of-concept provides a critical bridge between Phase 1 and Phase 2 trials, making an experienced CRO partner vital to achieving optimal outcomes for early-phase clinical research.
-
![Clinical Trial Recruitment Reinvented]( "Clinical Trial Recruitment Reinvented")
Clinical Site Services (CSS) is the industry leader in delivering strategic patient recruitment and enrollment solutions to study sites, sponsors and CROs.
-
![GettyImages-1352603244-laptop-man-typing-technology-office]( "User Acceptance Testing (UAT): Keeping Trials On Track")
Validate endpoint performance and security before deployment with structured UAT that reduces risk, ensures compliance, and enhances user experience through real-world testing.
-
![GettyImages-953449116 clinical trial oversight]( "Smarter Oversight, Earlier Action")
When risk-based oversight is reduced to a compliance checkbox, critical signals can be missed and escalate into systemic issues.
-
![iStock-187467661-quality-control-inspection]( "Navigating The Use Of Controlled Substances In Clinical Trials Using IRT")
Sponsor organizations that want to use controlled substances in clinical studies must manage the associated regulatory and logistical requirements. Read how this can be challenging for emerging biopharma.
